TOKYO — Japanese biotechnology company PrimRNA will launch clinical trials for a treatment using messenger RNA to repair osteoarthritis of the knee, a condition that afflicts many older adults.
Phase 1 trials to start as soon as September with aim to market shot in the 2030s
The work done by University of Osaka professor Keiji Itaka and his research team led to the clinical trials. (Photo provided by Keiji Itaka)
SATOSHI KAWAHARA
August 8, 2025 06:32 JST
Read Next
Sponsored Content
About Sponsored ContentThis content was commissioned by Nikkei’s Global Business Bureau.
